The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy

Publication date: Available online 25 February 2020Source: Pharmacology &TherapeuticsAuthor(s): L.-J. Palmieri, J. Lavolé, S. Dermine, C. Brezault, M. Dhooge, A. Barré, S. Chaussade, R. Coriat
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research

Related Links:

ConclusionsTo support decision making following progression to immunotherapy-based treatment in patients with advanced wild-type lung adenocarcinoma, a consensus document has been developed.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
uglakos Immunotherapy has considerably increased the number of anticancer agents in many tumor types including metastatic colorectal cancer (mCRC). Anti-PD-1 (programmed death 1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) immune checkpoint inhibitors (ICI) have been shown to benefit the mCRC patients with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). However, ICI is not effective in mismatch repair proficient (pMMR) colorectal tumors, which constitute a large population of patients. Several clinical trials evaluating the efficacy of immunotherapy combined with che...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Purpose of review To report the available information on the current status and future direction of the use of checkpoint inhibitors as novel immunotherapeutic agents in bladder cancer. Recent findings In the past 3 years, five immunotherapies targeting programmed cell death 1 (Pembrolizumab and Durvalumab) or programmed cell death-ligand 1 (PD-L1) (Atezolizumab, nivolumab and Avelumab) pathways have been approved in second-line setting for patients who progressed during or after cisplatin-based chemotherapy. According to the most recent update, these patients should be PD-L1-positive to be eligible for immunotherapy....
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: BLADDER CANCER: Edited by Juan Palou and Óscar Rodríguez Faba Source Type: research
Condition:   IIIA Stage Non-small Cell Lung Cancer Intervention:   Drug: Sintilimab Injection Sponsor:   First Hospital of Jilin University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: Immunotherapy seems a valid treatment option for high grade, poorly differentiated neoplasms. Future trials should explore the combination of immunotherapy with other agents, such as anti-angiogenic or other immunotherapy agents, in order to evaluate potential efficacy in low and intermediate grades, well differentiated tumors.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusions: AZD8186 has single agent efficacy in PTEN-deficient TNBC cell lines in vitro, but has limited single agent efficacy in vivo. However, AZD8186 has enhanced efficacy when combined with paclitaxel and anti-PD1 in vivo. Further study is needed to determine optimal combination therapies for PTEN-deficient solid tumors. PMID: 32215185 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
ichele Orditura Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC p...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Such newer treatments may seem miraculous, but they have drawbacks that chemo, even with it’s sometimes terrible side effects, doesn’t.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news
Authors: Singh SP, Singh R, Gupta OP, Gupta S, Brahma Bhatt ML Abstract Mounting evidence from the literature suggests the existence of a subpopulation of cancer stem cells (CSCs) in almost all types of human cancers. These CSCs possessing a self-renewal capacity inhabit primary tumors and are more defiant to standard antimitotic and molecularly targeted therapies which are used for eliminating actively proliferating and differentiated cancer cells. Clinical relevance of CSCs emerges from the fact that they are the root cause of therapy resistance, relapse, and metastasis. Earlier, surgery, chemotherapy, and radiot...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Condition:   Locally Advanced and Metastatic Pancreatic Cancer Interventions:   Drug: PD-L1/CTLA4 BsAb;   Combination Product: GP;   Combination Product: FOLFIRINOX Sponsor:   Changhai Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Immunotherapy